search
Back to results

Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease

Primary Purpose

Polycystic Kidney, Autosomal Dominant

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Weight Loss
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Polycystic Kidney, Autosomal Dominant

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Aged 18-65 years
  2. ADPKD diagnosis based on the modified Pei-Ravine criteria
  3. BMI 25-45 kg/m^2
  4. Normal to mildly declined renal function with an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 by the CKD-EPI equation
  5. Access to the internet with video chat capabilities
  6. No plans for extended travel (>2 weeks) during the 3 month intesive period
  7. Not currently participating in another interventional study or weight loss program
  8. Ability to provide informed consent

Exclusion Criteria:

  1. Diabetes mellitus (diagnosis or fasting glucose >126 mg/dL or Hemoglobin A1C >6.5%)
  2. Current nicotine use or history of use in the past 12 months
  3. Alcohol or substance abuse (self-report or undergoing treatment)
  4. History of hospitalization or major surgery within the last 3 months
  5. Untreated dyslipidemia (low density lipoprotein cholesterol > 190 mg/dL or triglycerides >400 mg/dL)
  6. Uncontrolled hypertension (systolic blood pressure > 160 or diastolic blood pressure >100 mm Hg)
  7. Pregnancy, lactation, or unwillingness to use adequate birth control
  8. Cardiovascular disease, peripheral vascular disease, cerebrovascular disease, significant pulmonary or gastrointestinal disease (described below), cancer (within the last 5 years, except skin cancer or other cancers considered cured with excellent prognosis)
  9. Abnormal resting electrocardiogram (ECG): serious arrhythmias, including multifocal PVC's, frequent PVC's (defined as 10 or more per min), ventricular tachycardia (defined as runs of 3 or more successive PVC's), or sustained atrial tachyarrhythmia; 2nd or 3rd degree A-V block, QTc interval > 480 msec or other significant conduction defects
  10. Significant gastrointestinal disorders including: chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, ulcerative colitis, chronic diarrhea, or active gallbladder disease
  11. Significant pulmonary disorders including: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, or uncontrolled asthma
  12. Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism (e.g. appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants; Study M.D. will be consulted as needed; antibiotics started during the intervention period are not an exclusion); regular use of obesity pharmacotherapeutic agents within the last 6 month
  13. History of clinically diagnosed eating disorder including anorexia nervosa, bulimia, binge eating disorder
  14. Weight loss >5% in past 3 months for any reason except post-partum weight loss; weight gain >5% in past 3 months requires assessment by PI to determine reason for weight gain and if it is appropriate for the subject to participate in the study.
  15. Untreated hyper- or hyperthyroidism (TSH outside of normal range for laboratory or history of uncontrolled thyroid disorder). History of thyroid disorder or current thyroid disease treated with stable medication regimen for at least 6 months in acceptable.
  16. Current severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode.
  17. History of other significant psychiatric illness (e.g. psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to dietary interventions.
  18. Inability to cooperate with/clinical contraindication for MRI including severe claustrophobia, implants, devices, or non-removable body piercings

Sites / Locations

  • Kristen Nowak

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Daily Caloric Restriction

Intermittent Fasting

Arm Description

The daily caloric restriction group will be instructed to reduce energy intake by a 34% daily energy deficit from baseline individual weight maintenance energy requirements.

Participants in the intermittent fasting group will be instructed to reduce energy intake to ~20% of estimated energy requirement (delivered as a single meal) three non-consecutive days per week, resulting in a weekly energy deficit of ~34% (similar to the daily caloric restriction group).

Outcomes

Primary Outcome Measures

Feasibility to Enroll and Retain Participants
Numbers of individuals pre-screened
Feasibility to Enroll Participants
Numbers of individuals screened
Feasibility to Retain Participants
Numbers of individuals enrolled
Feasibility to Retain Participants
Numbers of individuals retained
Percent Change From Baseline Body Weight (Weight Loss)
Measurement of body weight pre to post intervention in each group

Secondary Outcome Measures

Safety and Tolerability, Measured as Adverse Events
Number of participants with treatment-related adverse events in each group as evaluated by monthly phone questionnaire
Quality of Life Scores at Baseline
Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome.
Quality of Life Scores at 12 Weeks
Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome.
Quality of Life Scores at 1 Year
Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome.
Mood at Baseline
Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores for the Vigor scale range from 0 to 32, with higher scores for indicating a better outcome. Possible scores for the fatigue scale range from 0 to 28 with higher scores indicating a worse outcome.
Mood at 12 Weeks
Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores range from 0 to 20 for both the Vigor and Fatigue subscales, with higher scores indicating a worse outcome.
Mood at 1 Year
Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores range from 0 to 20 for both the Vigor and Fatigue subscales, with higher scores indicating a worse outcome.
Change in Energy Intake
Self-reported energy intake
Change in Macronutrient Intake
Self-reported macronutrient intake
Serum Insulin-like Growth Factor-1 Levels at Baseline
Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group
Serum Insulin-like Growth Factor-1 Levels at 12 Weeks
Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group
Serum Insulin-like Growth Factor-1 Levels at 1 Year
Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group
Insulin-like Growth Factor Binding Protein-1 Levels at Baseline
Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group
Insulin-like Growth Factor Binding Protein-1 Levels at 12 Weeks
Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group
Insulin-like Growth Factor Binding Protein-1 Levels at 1 Year
Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group
Change in PBMC Ratio of pS6K/s6K
Ratio of protein expression of phosphorylated S6K to S6K peripheral blood mononuclear cell protein expression of S6 kinase (S6K) in each group.
Change in PBMC pAMPK/AMPK Expression
Ratio of peripheral blood mononuclear cell protein expression of phosphorylated AMP-activated kinase (AMPK) to AMPK in each group
Percent Change in Total Kidney Volume by Magnetic Resonance Imaging (MRI)
Percent change from baseline in height adjusted total kidney volume by MRI in each group

Full Information

First Posted
October 27, 2017
Last Updated
February 8, 2022
Sponsor
University of Colorado, Denver
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT03342742
Brief Title
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
Official Title
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
June 4, 2018 (Actual)
Primary Completion Date
October 13, 2020 (Actual)
Study Completion Date
October 13, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The proposed research will determine the feasibility of delivering two behavioral weight loss interventions for 1 year in adults with autosomal dominant polycystic kidney disease (ADPKD) who are overweight or obese. The study will also compare these two interventions in terms of safety, acceptability, and tolerability. Last, this pilot trial will provide initial insight into a) biological changes and b) changes in kidney growth with each of the two weight loss interventions.
Detailed Description
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by development and continued growth of numerous fluid-filled renal cysts that ultimately result in renal failure. Similar to the general population, the prevalence of overweight and obesity have been rising in ADPKD patients, effecting about two-thirds of individuals. Surprisingly, the role of obesity in ADPKD progression is currently unknown. The investigators have novel preliminary data that overweight and obesity are independently associated with substantially faster kidney growth in ADPKD patients. Furthermore, in rodent models of ADPKD, mild-to-moderate food restriction profoundly slows cyst growth and maintains renal function via mechanisms including AMPK-activated kinase pathway activation and suppression of mammalian target of rapamycin/S6 kinase signaling and insulin-like growth factor-1 levels. Collectively, these data suggest that dietary restriction regimens may slow ADPKD progression. Accordingly, the primary aim is to determine the feasibility of delivering a 1 year behavioral weight loss intervention program in 30 overweight/obese adults with ADPKD, based on either daily caloric restriction (DCR) or intermittent fasting (IMF), with a similar (~34%) targeted weekly energy deficit. A key secondary goal is to evaluate safety, acceptability, and tolerability of IMF in ADPKD versus DCR. Last, the third exploratory aim is to a) obtain mechanistic insight into biological pathways that may be altered and b) provide initial insight into any changes in total kidney volume by magnetic resonance imaging with IMF and/or DCR.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polycystic Kidney, Autosomal Dominant

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
29 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Daily Caloric Restriction
Arm Type
Experimental
Arm Description
The daily caloric restriction group will be instructed to reduce energy intake by a 34% daily energy deficit from baseline individual weight maintenance energy requirements.
Arm Title
Intermittent Fasting
Arm Type
Experimental
Arm Description
Participants in the intermittent fasting group will be instructed to reduce energy intake to ~20% of estimated energy requirement (delivered as a single meal) three non-consecutive days per week, resulting in a weekly energy deficit of ~34% (similar to the daily caloric restriction group).
Intervention Type
Behavioral
Intervention Name(s)
Weight Loss
Intervention Description
Weight loss behavioral intervention via one of two strategies.
Primary Outcome Measure Information:
Title
Feasibility to Enroll and Retain Participants
Description
Numbers of individuals pre-screened
Time Frame
Through study completion, an expected duration of 18 months
Title
Feasibility to Enroll Participants
Description
Numbers of individuals screened
Time Frame
Through study completion, an expected duration of 18 months
Title
Feasibility to Retain Participants
Description
Numbers of individuals enrolled
Time Frame
Through study completion, an expected duration of 18 months
Title
Feasibility to Retain Participants
Description
Numbers of individuals retained
Time Frame
Through study completion, an expected duration of 18 months
Title
Percent Change From Baseline Body Weight (Weight Loss)
Description
Measurement of body weight pre to post intervention in each group
Time Frame
Baseline, 12 weeks, and 1 year
Secondary Outcome Measure Information:
Title
Safety and Tolerability, Measured as Adverse Events
Description
Number of participants with treatment-related adverse events in each group as evaluated by monthly phone questionnaire
Time Frame
1 year
Title
Quality of Life Scores at Baseline
Description
Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome.
Time Frame
Baseline
Title
Quality of Life Scores at 12 Weeks
Description
Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome.
Time Frame
12 Weeks
Title
Quality of Life Scores at 1 Year
Description
Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score. The Rand-36 measures quality of life. Possible scores for each subscale range from 0 to 100, with higher scores indicating a better quality of life and better outcome.
Time Frame
1 Year
Title
Mood at Baseline
Description
Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores for the Vigor scale range from 0 to 32, with higher scores for indicating a better outcome. Possible scores for the fatigue scale range from 0 to 28 with higher scores indicating a worse outcome.
Time Frame
Baseline
Title
Mood at 12 Weeks
Description
Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores range from 0 to 20 for both the Vigor and Fatigue subscales, with higher scores indicating a worse outcome.
Time Frame
12 Weeks
Title
Mood at 1 Year
Description
Mood state will be assessed with the Profile of Mood States 2 (POMS-2). The POMS-2 measures mood. Possible scores range from 0 to 20 for both the Vigor and Fatigue subscales, with higher scores indicating a worse outcome.
Time Frame
1 Year
Title
Change in Energy Intake
Description
Self-reported energy intake
Time Frame
Baseline, 12 weeks and 1 year
Title
Change in Macronutrient Intake
Description
Self-reported macronutrient intake
Time Frame
Baseline, 12 weeks and 1 year
Title
Serum Insulin-like Growth Factor-1 Levels at Baseline
Description
Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group
Time Frame
Baseline
Title
Serum Insulin-like Growth Factor-1 Levels at 12 Weeks
Description
Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group
Time Frame
12 Weeks
Title
Serum Insulin-like Growth Factor-1 Levels at 1 Year
Description
Serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group
Time Frame
1 Year
Title
Insulin-like Growth Factor Binding Protein-1 Levels at Baseline
Description
Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group
Time Frame
Baseline
Title
Insulin-like Growth Factor Binding Protein-1 Levels at 12 Weeks
Description
Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group
Time Frame
12 Weeks
Title
Insulin-like Growth Factor Binding Protein-1 Levels at 1 Year
Description
Insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group
Time Frame
1 Year
Title
Change in PBMC Ratio of pS6K/s6K
Description
Ratio of protein expression of phosphorylated S6K to S6K peripheral blood mononuclear cell protein expression of S6 kinase (S6K) in each group.
Time Frame
Baseline and 1 year
Title
Change in PBMC pAMPK/AMPK Expression
Description
Ratio of peripheral blood mononuclear cell protein expression of phosphorylated AMP-activated kinase (AMPK) to AMPK in each group
Time Frame
Baseline and 1 year
Title
Percent Change in Total Kidney Volume by Magnetic Resonance Imaging (MRI)
Description
Percent change from baseline in height adjusted total kidney volume by MRI in each group
Time Frame
Baseline and 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18-65 years ADPKD diagnosis based on the modified Pei-Ravine criteria BMI 25-45 kg/m^2 Normal to mildly declined renal function with an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 by the CKD-EPI equation Access to the internet with video chat capabilities No plans for extended travel (>2 weeks) during the 3 month intesive period Not currently participating in another interventional study or weight loss program Ability to provide informed consent Exclusion Criteria: Diabetes mellitus (diagnosis or fasting glucose >126 mg/dL or Hemoglobin A1C >6.5%) Current nicotine use or history of use in the past 12 months Alcohol or substance abuse (self-report or undergoing treatment) History of hospitalization or major surgery within the last 3 months Untreated dyslipidemia (low density lipoprotein cholesterol > 190 mg/dL or triglycerides >400 mg/dL) Uncontrolled hypertension (systolic blood pressure > 160 or diastolic blood pressure >100 mm Hg) Pregnancy, lactation, or unwillingness to use adequate birth control Cardiovascular disease, peripheral vascular disease, cerebrovascular disease, significant pulmonary or gastrointestinal disease (described below), cancer (within the last 5 years, except skin cancer or other cancers considered cured with excellent prognosis) Abnormal resting electrocardiogram (ECG): serious arrhythmias, including multifocal PVC's, frequent PVC's (defined as 10 or more per min), ventricular tachycardia (defined as runs of 3 or more successive PVC's), or sustained atrial tachyarrhythmia; 2nd or 3rd degree A-V block, QTc interval > 480 msec or other significant conduction defects Significant gastrointestinal disorders including: chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, ulcerative colitis, chronic diarrhea, or active gallbladder disease Significant pulmonary disorders including: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, or uncontrolled asthma Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism (e.g. appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants; Study M.D. will be consulted as needed; antibiotics started during the intervention period are not an exclusion); regular use of obesity pharmacotherapeutic agents within the last 6 month History of clinically diagnosed eating disorder including anorexia nervosa, bulimia, binge eating disorder Weight loss >5% in past 3 months for any reason except post-partum weight loss; weight gain >5% in past 3 months requires assessment by PI to determine reason for weight gain and if it is appropriate for the subject to participate in the study. Untreated hyper- or hyperthyroidism (TSH outside of normal range for laboratory or history of uncontrolled thyroid disorder). History of thyroid disorder or current thyroid disease treated with stable medication regimen for at least 6 months in acceptable. Current severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode. History of other significant psychiatric illness (e.g. psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to dietary interventions. Inability to cooperate with/clinical contraindication for MRI including severe claustrophobia, implants, devices, or non-removable body piercings
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristen Nowak, Ph.D., MPH
Organizational Affiliation
University of Colorado - Anschutz Medical Campus
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kristen Nowak
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data obtained through this study may be provided to qualified researchers with academic interest in ADPKD. Data shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. data use agreement) are prerequisites to the sharing of data with the requesting party.
IPD Sharing Time Frame
Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.
IPD Sharing Access Criteria
Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).

Learn more about this trial

Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease

We'll reach out to this number within 24 hrs